WebRegorafenib, a multikinase inhibitor targeting the RAS/RAF/MEK/ERK pathway, is used for the treatment of colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. The data on cardiotoxicity of regorafenib are limited. Web4 ian. 2024 · Multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have rapidly become an established factor in daily (hemato)-oncology practice. ... Clinically relevant drug interactions with multikinase inhibitors: a review. Koen G. A. M. Hussaarts ... One of the most promising classes of targeted anticancer agents are the ...
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a ...
WebTyrosine kinase inhibitors (TKI) are effective in the targeted treatment of various malignancies. Imatinib was the first to be introduced into clinical oncology, and it was … Web29 mar. 2024 · PDF Background: According to the Barcelona Clinic Liver Cancer (BCLC) staging system, only the advanced stage (stage C) hepatocellular carcinoma (HCC)... Find, read and cite all the research ... shooting in uvalde texas gunman
Dual Inhibitors of Human DNA Topoisomerase II and Other …
Web22 nov. 2012 · Regorafenib is the first small-molecule multikinase inhibitor with survival benefits in metastatic colorectal cancer which has progressed after all standard therapies. The present study provides evidence for a continuing role of targeted treatment after disease progression, with regorafenib offering a potential new line of therapy in this treatment … Web1 oct. 2006 · Compound 4 was found to be orally available in mice, and to inhibit the growth of HCT116 xenografts in vivo, thereby providing proof of principle for this new kinase … Web3 mar. 2024 · Drug classes: Multikinase inhibitors, VEGF/VEGFR inhibitors. Medically reviewed by Drugs.com on Mar 3, 2024. Written by Cerner Multum. Uses; Warnings; … shooting in uvalde